Literature DB >> 20585270

Acral cutaneous melanoma in a Spanish Caucasian population.

José Antonio Avilés-Izquierdo1, Maria Isabel Longo-Imedio, Pablo Lázaro-Ochaita.   

Abstract

Acral lentiginous melanoma (ALM) is the most frequent type of cutaneous melanoma in the Asian and African populations, but the fourth distinct variant of cutaneous melanoma in the Caucasian population. Histological criteria and prognosis of ALM remain controversial. A retrospective study, showing epidemiological, clinical, histological and survival characteristics of melanomas located on acral sites (acral cutaneous melanoma) compared with nonacral melanomas. Fifty-two of 552 melanomas (9.42%) were located on acral sites. Histological examination revealed ALMs in 30 cases (61%), nodular melanomas in seven cases (14.3%) and superficial spreading melanomas in five cases (10.2%). Patients with ulcerated melanomas had an older mean age (62.3 vs. 57.2 years) (P=0.02). Tumour thickness was greater in acral melanomas (2.8 vs. 1.9 mm) (P=0.039). Overall survival and disease-free survival did not differ significantly from melanomas on other sites. Acral cutaneous melanoma has peculiar epidemiological features in the Spanish population. They are more frequent in patients above 65 years of age and they have a greater tumour thickness, but they are not significantly associated with a lower survival.

Entities:  

Year:  2010        PMID: 20585270     DOI: 10.1097/CMR.0b013e3282f1d2b6

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  1 in total

1.  Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Authors:  Sanxiong Xu; Zuozhang Yang; Jinyu Zhang; Yongxin Jiang; Yongbin Chen; Hongjun Li; Xuefeng Liu; Da Xu; Yanjin Chen; Yihao Yang; Ya Zhang; Dongxu Li; Junfeng Xia
Journal:  DNA Cell Biol       Date:  2015-01       Impact factor: 3.311

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.